| Liver carcinoma

Stivarga vs Yervoy

Side-by-side clinical, coverage, and cost comparison for liver carcinoma.

Deep comparison between: Stivarga vs Yervoy with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsYervoy has a higher rate of injection site reactions vs Stivarga based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Yervoy but not Stivarga, including UnitedHealthcare

Category

Stivarga

Yervoy

At A Glance

RouteOral

FrequencyOnce daily (21 of 28 days)

ClassMultikinase inhibitor

RouteIV infusion

FrequencyEvery 3 weeks (monotherapy) or every 6 weeks (combination)

ClassCTLA-4 antagonist

Indications

Metastasis from malignant neoplasm of colon and/or rectum
Gastrointestinal Stromal Tumors
Liver carcinoma

melanoma
Renal Cell Carcinoma
Colorectal Carcinoma
Liver carcinoma
Non-Small Cell Lung Carcinoma
Malignant Pleural Mesothelioma
Squamous cell carcinoma of esophagus

Dosing

Metastasis from malignant neoplasm of colon and/or rectum, Gastrointestinal Stromal Tumors, Liver carcinoma 160 mg orally once daily for the first 21 days of each 28-day cycle, taken after a low-fat meal; continue until disease progression or unacceptable toxicity.

Melanoma (unresectable or metastatic) 3 mg/kg IV every 3 weeks for 4 doses, or 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for 4 doses followed by nivolumab monotherapy

Melanoma (adjuvant) 3 mg/kg IV every 3 weeks for 4 doses, then 3 mg/kg every 12 weeks for up to 4 additional doses

Renal Cell Carcinoma 1 mg/kg IV with nivolumab 3 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab monotherapy

Colorectal Carcinoma 1 mg/kg IV with nivolumab 240 mg or 3 mg/kg IV (weight-based) every 3 weeks for 4 doses, followed by nivolumab monotherapy

Liver carcinoma 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for up to 4 doses, followed by nivolumab monotherapy

Non-Small Cell Lung Carcinoma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks, or with nivolumab and 2 cycles of platinum-doublet chemotherapy

Malignant Pleural Mesothelioma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks

Squamous cell carcinoma of esophagus 1 mg/kg IV every 6 weeks with nivolumab 3 mg/kg every 2 weeks or 360 mg every 3 weeks

Contraindications

—

Drug Interactions

1112View drug interactions

676View drug interactions

Adverse Reactions

Most common (>=20%) pain, HFSR/PPES, asthenia/fatigue, diarrhea, decreased appetite/food intake, hypertension, infection, dysphonia, hyperbilirubinemia, fever, mucositis, weight loss, rash, nausea

Serious hepatotoxicity, infections, hemorrhage, gastrointestinal perforation or fistula, dermatological toxicity, hypertension, cardiac ischemia and infarction, reversible posterior leukoencephalopathy syndrome

Postmarketing hypersensitivity reaction, nephrotic syndrome, cardiac failure, arterial aneurysms/dissections/rupture

Most common (>=20%) fatigue, diarrhea, rash, pruritus, nausea, pyrexia, musculoskeletal pain, decreased appetite, cough, headache, dyspnea, vomiting, abdominal pain, arthralgia

Serious immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, dermatologic reactions, neurological toxicities, myocarditis, adrenal insufficiency, hypophysitis, hyperthyroidism, hypothyroidism

Pharmacology

Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in oncogenesis, tumor angiogenesis, metastasis, and tumor immunity, including VEGFR1-3, KIT, PDGFR-alpha/beta, FGFR1/2, RAF-1, BRAF, and CSF1R.

Ipilimumab blocks CTLA-4, a negative regulator of T-cell activity, thereby augmenting T-cell activation and proliferation including tumor-infiltrating T-effector cells and reducing T-regulatory cell function.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Stivarga